Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Beijing InnoCare Pharma Tech Co: Clinical Trials & FDA Approval Profile

Beijing InnoCare Pharma Tech Co (Global / Institutional) sponsors 45 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 23 active protocols (16 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)60 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Beijing InnoCare Pharma Tech Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)45
Active Pipeline (Recruiting Now)23 (16)
Completed vs Stopped Early7 / 0 (0.0%)
Median Closed Actual Enrollment60 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Beijing InnoCare Pharma Tech Co
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong16
The First Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi14
Henan Provincial People's HospitalZhengzhou14

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Beijing InnoCare Pharma Tech Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07378527Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaPhase II/IIIRECRUITING
NCT06842199Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque PsoriasisPhase IIIRECRUITING
NCT07440537Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyPhase IIRECRUITING
NCT07047612ICP-332 in Subjects With Non-segmental VitiligoPhase II/IIIRECRUITING
NCT06775860ICP-332 in Subjects With Moderate to Severe Atopic DermatitisPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Beijing InnoCare Pharma Tech Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI